Knight
Highly Engaged Employees
Manufacturing · Canada · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
100 Boul. Alexis-nihon Bureau 600, Montr...Phone Number
(514) 484-4483Website
www.knighttx.comRevenue
$236.3 MillionIndustry
About Knight
Knight Org Chart
Is Knight your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Knight, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Knight had a recent Job posting/layoffs
Product Launch: Get notified when Knight launches new products
Website visits: Recent activity has been detected on your website
Check if Knight has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Knight recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Knight
Funding: Get notified immidiatlly once Knight has new funding data
Check out if Knight is spiking on competitors!
Recommended Actions
Find VP level buyers at Knight
Find more new buyers
Company Profile Activity
Activity Insights
Knight is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Knight is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Knight.
Knight Tech Stack
A closer look at the technologies used by Knight
Most Recent Scoops
Knight News & Media
Knight Therapeutics Reports Second Quarter 2026 Results
Increased 2026 guidance and expect revenues of $540 million to $560 million Achieved six month record-high revenues of $293 million and Adjusted EBITDA1 of $52 millionNotice of Knight Therapeutics' Second Quarter 2026 Results Conference Call
MONTREAL, July 30, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-US) pharmaceutical company, will release its second quarter 2026 financial results on Thursday, August 6, 2026 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.Notice of Knight Therapeutics' Second Quarter 2026 Results Conference Call
MONTREAL, July 30, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-US) pharmaceutical company, will release its second quarter 2026 financial results on Thursday, August 6, 2026 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.Knight Therapeutics Announces Repayment of Revolving Credit Facility
MONTREAL, June 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has repaid all amounts outstanding under its revolving credit facility with National Bank of Canada and a syndicate of lenders.
Top Manufacturing Companies
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Knight
Knight Therapeutics Inc., headquartered in Montreal, is a specialty pharmaceutical company focused on acquiring, licensing, marketing, and commercializing innovative prescription medicines across Canada and Latin America. With operations in multiple countries, it delivers a diverse portfolio of pharmaceuticals while building long-term partnerships... Read More